Magrolimab
Based on 4 publication(s) in Google Scholar
Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab, an IgG4 isotype, lacks ADCC function and exhibits relatively weak ADCP effector function. Magrolimab can be used for the study of malignant bone tumors and breast cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.92%
- CAS 番号: 2169232-81-7
- 分子量:145.73 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Magrolimab
More
生物活性
Human IgG4 kappa
Human
CD47
Magrolimab (10 μg/mL, 24 h) can promote the phagocytic activity of tumor associated macrophages towards ovarian or breast tumor cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Humanized and non-humanized ES xenograft NSG-SGM3 mice[1].
-
Dosage:12-100 μg
-
Administration:Intraperitoneal injection (i.p.); once daily; 10 days
-
Result:Inhibited tumor growth and lung metastasis, and prolonged animal survival time.
-
Animal Model:4-8 weeks old NSG female breast cancer mouse model[2].
-
Dosage:250 μg
-
Administration:Intraperitoneal injection (i.p.); once every two days; 7 weeks (implanted GFP/luciferase BT474 cells into the left mammary fat pad of female mice)
-
Result:Restricted the Growth of HER2 ADCC-Tolerant Tumors.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
化学情報
-
CAS 番号 2169232-81-7
-
性状 Liquid
-
分子量 145.73 kDa
-
Color Colorless to light yellow
-
SMILES
[Magrolimab]
-
別名
Hu5F9-G4
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Int J Mol Sci
GV1001 Reprograms CD47 Immune Checkpoint to Restore Macrophage Antitumor Activity in Oral Squamous Cell Carcinoma. [Abstract]2026 Apr 7;27(7):3340. PMID: 41977514 -
Mol Carcinog
Therapeutic Potential of IL-37 in Cervical Cancer: Suppression of Tumour Progression and Enhancement of CD47-Mediated Macrophage Phagocytosis. [Abstract]2025 Mar;64(3):425-439. PMID: 39620401 -
Blood Transfus
Pretreatment with Daudi cells eliminates anti-CD47 monoclonal antibody interference in immunohematology testing. [Abstract]2024 Jan;22(1):20-29. PMID: 37847207 -
Transfusion
Anti-CD47 drug interference in pre-transfusion testing can be overcome by antigen masking. [Abstract]2025 Aug 13. PMID: 40799186
純度とドキュメンテーション
-
データシート (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Luo W, et al. A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma. Front Immunol. 2023 Oct 6;14:1277987. [Content Brief]
[2]. Upton R, et al. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2026849118. [Content Brief]
[3]. Liu Y, et al. PARP inhibition synergizes with CD47 blockade to promote phagocytosis by tumor-associated macrophages in homologous recombination-proficient tumors. Life Sci. 2023 Aug 1;326:121790. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Powered by Bioz